Advances in antibody-drug conjugate-based combination therapy strategies for non-small cell lung cancer

Lung

 1 min.

Non-small cell lung cancer (NSCLC) continues to be one of the leading causes of cancer death worldwide. Although targeted therapies and immune checkpoint inhibitors have meaningfully improved outcomes for some patients, many still lack targetable mutations or quickly develop resistance. Antibody-drug...